Form 4: Vor Biopharma Director Receives Stock Option Grant

Director Alexander Cumbo was granted 56,345 stock options in Vor Biopharma Inc. as part of a standard equity compensation arrangement.

Summary

• Director Alexander Cumbo acquired 56,345 stock options in Vor Biopharma Inc. (VOR).
• The options have an exercise price of $14.09 per share.
• The grant date for the transaction was June 11, 2026.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation rather than a change in company strategy or financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of VOR common stock.
• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The options vest monthly over a 36-month period starting July 11, 2026, contingent on continued service.

Management Comments

• No specific management commentary provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate milestones.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for mid-cap and small-cap biotech firms.
• The 36-month vesting schedule is a common retention mechanism used by companies like Vor Biopharma to ensure board stability.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Director to begin vesting of options on July 11, 2026.

Key Dates

Keywords

Vor Biopharma, VOR, Form 4, Insider Trading, Stock Options, Director Compensation